-Several epidemiologic and clinical studies show that following myocardial infarction, dietary supplements of -3 polyunsaturated fatty acids (3FA) reduce sudden death. Animal data show that 3FA have antiarrhythmic properties, but their mechanisms of action require further elucidation. The effects of 3FA supplementation were studied in female rabbits to analyze whether their antiarrhythmic effects are due to a reduction of triangulation, reverse use-dependence, instability, and dispersion (TRIaD) of the cardiac action potential (TRIaD as a measure of proarrhythmic effects). In Langendorffperfused hearts challenged by a selective rapidly activating delayed rectifier potassium current inhibitor that has been shown to exhibit proarrhythmic effects (dofetilide; 1 to 100 nM), 3FA pretreatment (30 days; n ϭ 6) prolonged the plateau phase of the monophasic action potential; did not slow the terminal fast repolarization; reduced the dofetilide-induced prolongation of the action potential duration; reduced dofetilide-induced triangulation; and reduced dofetilide-induced reverse use-dependence, instability of repolarization, and dispersion. Dofetilide reduced excitability in 3FA-pretreated hearts but not in control hearts. Whereas torsades de pointes (TdP) were observed in five out of six in control hearts, none were observed in 3FA-pretreated hearts. Docosahexaenoic acid (DHA) inhibited the sodium current with ultrafast kinetics. Dietary 3FA supplementation markedly reduced dofetilide-induced TRIaD and abolished dofetilideinduced TdP. Ultrafast sodium channel block by DHA may account for the antiarrhythmic protection of the dietary supplements of 3FA against dofetilide-induced proarrhythmia observed in this animal model. antiarrhythmia agents; omega-3 fatty acids; ion channels; torsades de pointes ORAL SUPPLEMENTATION WITH fish oils or ethyl esters of -3 polyunsaturated fatty acids (3FA) are associated in some large clinical studies with significant risk reductions of sudden cardiac death, which, although not directly compared in a head-to-head trial, appear larger than those observed with amiodarone in similar study populations, with less toxicities (1,2,9,11,14,27). However, controversy exists about the pro-or antiarrhythmic effects of 3FA (8, 35). Antiarrhythmic effects of 3FA have been reported in animal (5, 33) and in cellular models (29). Similar to amiodarone, it has been reported that 3FA block sodium (42), calcium (41), and potassium channels (17, 24, 26); likewise, they also exhibit antiadrenergic actions (36). In contrast with amiodarone, at therapeutic concentrations, 3FA do not widen QRS or prolong the QT interval (13). Many class III antiarrhythmic drugs such as dofetilide, as well as noncardiac drugs, can be associated with a prolongation of the QTc interval of the electrocardiogram (ECG) and development of polymorphic ventricular arrhythmias torsades de pointes (TdP), an arrhythmia where the ECG exhibits characteristic twisting undulations of the cardiac activations. Therefore, QT prolongation itself is re...